glp-1 parkinson's disease Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative treatment glp 1 and parkinson's disease
Description
In addition to the Declaratory Order, FDA also published an update to its website entitled FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. This update also included FDAs enforcement policy described above, as well as stated that although dulaglutide remains in shortage, the manufacturers have reported all presentations are available
These medications were originally developed to manage diabetes
There was also a lower risk of suicidal behavior in people who used GLP-1s overall
Physiological Reviews, 2012
